Leap Therapeutics Stock Price

-0.04 (-3.51%)
Volume 400
Bid Price 1.04
Ask Price 1.18
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Leap Therapeutics Inc LPTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.04 -3.51% 1.10 08:01:51
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
5 400 - 0.92 - 4.17
Last Trade Time Type Quantity Stock Price Currency
08:00:13 formt 179 $ 1.10 USD


Draw Mode:

Leap Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 97.15M 88.32M 69.40M $ 1.50M $ - -0.46 -2.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.79M -

more financials information »

Leap Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.371.371.101.23708,245-0.27-19.71%
1 Month1.431.47650.921.21881,383-0.33-23.08%
3 Months1.992.080.921.51744,724-0.89-44.72%
6 Months2.213.4490.922.271,339,876-1.11-50.23%
1 Year1.604.170.922.532,367,159-0.50-31.25%
3 Years1.534.170.57282.361,172,936-0.43-28.1%
5 Years6.6210.250.57282.44790,337-5.52-83.38%

Leap Therapeutics Description

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.
Your Recent History
Leap Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220524 12:33:38